Key result
An ERAS protocol for ureteroscopic stone treatment reduced the rate of patients discharged with an opioid prescription from 93% to 0% (p < 0.05).
Why the study?
Prescription opioids have contributed significantly to the opioid epidemic, prompting efforts to minimize their use during ureteroscopic stone treatment.
Does an ERAS protocol reduce opioid utilization in patients undergoing ureteroscopic stone treatment with stent placement?
Cohort (n=80)
Does an ERAS protocol reduce opioid utilization in patients undergoing ureteroscopic stone treatment with stent placement?
Absolute Event Rate: 0% vs 93%
p-value: p=<0.05
An ERAS protocol for ureteroscopic stone treatment effectively eliminates discharge opioid prescriptions without adversely affecting recovery or increasing postoperative clinical encounters.
Supports ERAS for minimizing discharge opioids after ureteroscopy; hypothesis-generating and requires RCTs before practice change.
Purpose: A large part of the national opioid epidemic has been tied to prescription opioids, leading to a push to reduce or eliminate their use when feasible. The objective of this study was to evaluate outcomes of implementing an Enhanced Recovery After Surgery (ERAS) protocol for patients undergoing ureteroscopic stone treatment with stent placement geared toward minimizing opioid use. Materials and Methods: We performed a pre–post study concerning a process improvement project of consecutive patients undergoing ureteroscopic stone treatment with stent placement utilizing a novel ERAS protocol. A lead-in period with patients managed conventionally with opioids was performed before implementation of the ERAS protocol. Data regarding opioid utilization, postoperative outcomes, and patient-reported outcomes, including Patient-Reported Outcomes Measurement Information System (PROMIS), were compared between groups. Results: There were 28 pre-ERAS patients and 52 ERAS-managed patients. Patients discharged with an opioid prescription decreased from 93% to 0% (p < 0.05). Mean total morphine milligram equivalent decreased from 60.1 ± 41 to 7.7 ± 26 (p < 0.05). There was no significant difference noted for postoperative calls for pain in the pre-ERAS vs ERAS groups (25% vs 19%, p = 0.9) or in unscheduled provider encounters (0% vs 4%, p = 0.46). There were no clinically significant differences between groups on patient-reported measures. Conclusions: Implementation of an ERAS protocol for ureteroscopic stone treatment resulted in a significant reduction in perioperative opioids, a total reduction in discharge opioid prescriptions, and ∼90% reduction in total 30-day postoperative opioid prescribing with no adverse effects on recovery or increase in postoperative clinical encounters.
No takes yet. Share an insight, caveat, or question.
Gridley et al. (2020) conducted a cohort in Ureteroscopic stone treatment (n=80). Enhanced Recovery After Surgery (ERAS) protocol vs. Conventional management with opioids was evaluated on Discharge with an opioid prescription (p=<0.05). An ERAS protocol for ureteroscopic stone treatment reduced the rate of patients discharged with an opioid prescription from 93% to 0% (p < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: